
The company has submitted an Abbreviated New Drug Application (ANDA) containing a 'paragraph IV' certification with the US Food and Drug Administration (FDA) for the product, a generic version of AstraZeneca's Olaparib tablets in strengths of 100mg and 150mg.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/82vLirD
via
IFTTT
0 comments:
Post a Comment